SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GLGC Gene Logic
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (69)7/15/1999 7:08:00 AM
From: Mike McFarland  Read Replies (2) of 360
 
Ah--I just found my file full of GLGC reports
from the brokerage houses, I will re-read those
and the annual report and then ask a better
question. Before I do that though, I woke up in
the middle of the night with the second iteration
of yesterday's question--here it is just for fun
in case somebody shows up on the thread before I
re-read my file:

Which molecular movie would a molecular
biologist rather have: The READS expression
profiles from a hundred patients in different
stages of a disease...or a hundred profiles from
the same tumor (or better--from a single
cell) as it undergoes it's various processes.

I guess that is really what the flow through
chip is for isn't it--to see gene expression
as tissue is exposed to various compounds, or
is the flow through chip mainly going to be used
to build the toxicology database?

I see from this year's annual report that one
of the goals of Gene Logic is to begin using
the Flow-Through chip--screening for leads.
I think I asked this once before, but I will
again: Where does Gene Logic get the library
of compounds from which to find candidates?

You know, I think I know what started this line
of questioning: The Celera/RPR press release.
Celera's GeneTag technology--any comments about
that? It sounds a lot like what Gene Logic is
trying to do with the flow through chip.
''It's a way of looking at all of the genes expressed in a biological system to see which ones are changing as part of a drug treatment, a disease state or a toxic response,'' Criss Walworth, a spokeswoman for Celera, said in a telephone interview.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News